Ignite Creation Date:
2025-12-24 @ 2:46 PM
Ignite Modification Date:
2025-12-24 @ 2:46 PM
Study NCT ID:
NCT07219459
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-10-21
First Post:
2025-10-20
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Sponsor:
CatalYm GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-02
Start Date Type:
ESTIMATED
Primary Completion Date:
2029-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-09
Completion Date Type:
ESTIMATED
First Submit Date:
2025-10-20
First Submit QC Date:
None
Study First Post Date:
2025-10-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-20
Last Update Post Date:
2025-10-21
Last Update Post Date Type:
ESTIMATED